Taken together, these findings highlight the critical role of the ERβ/circAHNAK/FMR1/ADAM17 axis in ccRCC progression and progression, suggesting that targeted inhibition of this pathway may represent a promising therapeutic strategy for ccRCC (Figure 10J). The gene discussed is ADAM17; the disease is nonpapillary renal cell carcinoma.